Medicine guide
ZIRABEV
As listed in the register: ZIRABEV 25 mg/ml, solution à diluer pour perfusion
25 mg · solution à diluer pour perfusion
- Prescription only
- Active substance
- Bévacizumab
- Made by
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Details
| Made by | PFIZER EUROPE MA EEIG (BELGIQUE) |
|---|---|
| Active substance | Bévacizumab |
| Strength | 25 mg |
| Form | solution à diluer pour perfusion |
| Route | intraveineuse |
| Dispensing (as stated by the register) | réservé à l'usage HOSPITALIER · prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE · liste I · prescription réservée aux médecins compétents en CANCEROLOGIE |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/18/1344 |
| Name in the register | ZIRABEV 25 mg/ml, solution à diluer pour perfusion |
| Packs | 1 flacon(s) en verre de 4 ml · 1 flacon(s) en verre de 16 ml |
| CIS | 64224872 |
| CIP13 | 3400955062387 |
| CIP13 | 3400955062394 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.
ABEVMY25 mgPrescription only BIOSIMILAR COLLABORATIONS IRELAND (IRLANDE) · BévacizumabALYMSYS25 mgPrescription only MABXIENCE RESEARCH (ESPAGNE) · BévacizumabAVASTIN25 mgPrescription only ROCHE REGISTRATION (ALLEMAGNE) · BévacizumabAYBINTIO25 mgPrescription only SAMSUNG BIOEPIS NL (PAYS-BAS) · BévacizumabMVASI25 mgPrescription only AMGEN EUROPE · BévacizumabOYAVAS25 mgPrescription only STADA ARZNEIMITTEL AG · Bévacizumab